ABORDAREA INDIVIDUALIZATĂ ÎN INSUFICIENȚA CARDIACĂ CU FRACȚIA DE EJECȚIE PĂSTRATĂ - DE LA PRACTICA CLINICĂ LA INTELIGENȚĂ ARTIFICIALĂ

Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023 Published. online ahead of print 12th February 2022; 118:3272–3287.

SA Carey et al. Probability of Accurate Heart Failure Diagnosis and the Implications for Hospital Readmissions. Am. J. Cardiol (2017).

Jesper Jensen1, Mikael Kjær Poulsen, Per Warrer Petersen, Bo Gerdes, Kasper Rossing and Morten Schou1. Prevalence of heart failure phenotypes and current use of therapies in primary care: results from a nationwide study. ESC Heart Failure (2023). Published online in Wiley Online Library (wileyonlinelibrary.com). DOI:10.1002/ehf2.14324.

Kalogeropoulos AP, Fonarow GC, Georgiopoulou V, Burkman G, Siwamogsatham S, Patel A, Li S, Papadimitriou L, Butler J. Characteristics and outcomes of adultoutpatients with heart failure andimprovedor recovered ejection fraction. JAMA Cardiol.2016;1:510–518.

Savarese G, Vedin O, D’Amario D, Uijl A, Dahlström U, Rosano G, Lam CSP, Lund LH. Prevalence and prognostic implications of longitudinal ejection fraction change in heart failure. JACC Heart Fail. 2019;7: 306–317.

Agra Bermejo R, Gonzalez Babarro E, López Canoa JN, Varela Román A, Gómez Otero I, Oro Ayude M, ParadaVazquez P, Gómez Rodríguez I, DíazCastro O, González Juanatey JR. Heart failure with recovered ejection fraction: clinical characteristics, determinants and prognosis. CARDIOCHUSCHOP registry. Cardiol J. 2018; 25: 353–362.

Tsuji K, Sakata Y, Nochioka K, Miura M,Yamauchi T, Onose T, Abe R, Oikawa T, Kasahara S, Sato M, ShirotoT, Takahashi J, Miyata S, Shimokawa H, on behalf of the CHART-2 Investigators. Characterization of heart failure patients with mid range left ventricular ejectionfraction a report from the CHART-2study. Eur J Heart Fail. 2017; 19:1258–1269.

Halliday BP, Wassall R, Lota AS, Khalique Z, Gregson J, Newsome S, Jackson R, Rahneva T, Wage R, Smith G, Venneri L,Tayal U, Auger D, Midwinter W, Whiffin N, Rajani R, Dungu JN, Pantazis A, Cook SA, Ware JS, Baksi AJ, Pennell DJ, Rosen SD, Cowie MR, Cleland JGF, Prasad SK. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet. 2019; 393:61–73.

Petar M. Seferovic , Panagiotis Vardas , Ewa A. Jankowska, Aldo P. Maggioni,Adam Timmis, Ivan Milinkovic, Marija Polovina, Chris P. Gale, Lars H. Lund, Yuri Lopatin, Mitja Lainscak, Gianluigi Savarese, Radu Huculeci, Dzianis Kazakiewicz, and Andrew J.S. Coats, in collaboration with the National Heart Failure Societies of the ESC member countries. The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019. European Journal of Heart Failure (2021) 23, 906–914.

Giuseppe M.C. Rosano, Petar Seferovic, Gianluigi Savarese, Ilaria Spoletini et. al. Impact analysis of heart failure across European countries: an ESC-HFA position paper. ESC Heart Failure 2022; 9: 2767–2778. Published online 22 July 2022 in Wiley Online Library, DOI: 10.1002/ ehf2.14076.

Alicja Jasinska-Piadlo, Patricia Campbell. Management of patients with heart failure and preserved ejection fraction. Published Online First 22 March 2023.

Gevaert, A.B.; Kataria, R.; Zannad, F.; Sauer, A.J.; Damman, K.; Sharma, K.; Shah, S.J.; Van Spall, H.G.C. Heart failure with preserved ejection fraction: Recent concepts in diagnosis, mechanisms and management. Heart 2022, 108, 1342–1350.

Vasan, R.S.; Levy, D. Defining diastolic heart failure: A call for standardized diagnostic criteria. Circulation 2012, 131, 1824–1831.

Reddy, Y.N.V.; Carter, R.E.; Obokata, M.; Redfield, M.M.; Borlaug, B.A. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation 2018, 138, 861–870.

Irina Cabac-Pogorevici, Balazs Muk, Yasmin Rustamova, Andreas Kalogeropoulos, Stylianos Tzeis, Panos Vardas. Ischaemic cardiomyopathy. Pathophysiological insights, diagnostic management and the roles of revascularisation and device treatment. Gaps and dilemmas in the era of advanced technology. European Journal of Heart Failure (2020)22, 789–799, doi:10.1002/ ejhf.1747.

Lindman, B.R.; Dávila-Román, V.G.; Mann, D.L.; McNulty, S.; Semigran, M.J.; Lewis, G.D.; de las Fuentes, L.; Joseph, S.M.; Vader, J.; Hernandez, A.F.; et al. Cardiovascular phenotype in HFpEF patients with or

without diabetes: A RELAX trial ancillary study. J. Am. Coll. Cardiol. 2014, 64.

Samson, R.; Jaiswal, A.; Ennezat, P.V.; Cassidy, M.; Le Jemtel, T.H. Clinical Phenotypes in Heart Failure with Preserved Ejection Fraction. J. Am. Heart Assoc. 2016, 5.

Almengló, C.; Fu, X.; Flores-Arias, M.T.; Fernández, Á.L.; Viñuela, J.E.; Martínez-Cereijo, J.M.; Durán, D.; Rodríguez-Mañero, M.; González-Juanatey, J.R.; Eiras, S. Synergism between obesity and HFpEF on neutrophils phenotype and its regulation by adipose tissue- molecules and SGLT2i dapagliflozin. J. Cell. Mol. Med. 2022, 26, 4416–4427. 19. Wang, A.; Li, Z.; Zhuo, S.; Gao, F.; Zhang, H.; Zhang, Z.; Ren, G.; Ma, X. Mechanisms of Cardiorenal Protection with SGLT2 Inhibitors in Patients with T2DM Based on Network Pharmacology. Front. Cardiovasc. Med. 2022, 9, 857952.

Van Ham, W.B.; Kessler, E.L.; Oerlemans, M.I.F.J.; Handoko, M.L.; Sluijter, J.P.G.; van Veen, T.A.B.; den Ruijter, H.M.; de Jager, S.C.A. Clinical Phenotypes of Heart Failure with Preserved Ejection Fraction to Select Preclinical Animal Models. JACC Basic Transl. Sci. 2022, 7, 844–857.

Irina Cabac-Pogorevici, Valeriu Revenco. Heart failure and central sleep apnea in the era of implantable recorders. AnatolJCardiol. 2021. DOI: 10.5152/6366.

Resoja, K.P.; Unterhuber, M.; Wachter, R.; Thiele, H.; Lurz, P. A cardiologist’s guide to machine learning in cardiovascular disease prognosis prediction. Basic Res. Cardiol. 2023, 118, 10.

Shah, S.J.; Katz, D.H.; Selvaraj, S.; Burke, M.A.; Yancy, C.W.; Gheorghiade, M.; Bonow, R.O.; Huang, C.C.; Deo, R.C. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation 2015, 131, 269–279.

Uijl, A.; Savarese, G.; Vaartjes, I.; Dahlström, U.; Brugts, J.J.; Linssen, G.C.M.; van Empel, V.; Brunner- La Rocca, H.P.; Asselbergs, F.W.; Lund, L.H.; et al. Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction. Eur. J. Heart Fail. 2021, 23, 973–982.

Casebeer, A.; Horter, L.; Hayden, J.; Simmons, J.; Evers, T. Phenotypic clustering of heart failure with preserved ejection fraction reveals different rates of hospitalization. J. Cardiovasc. Med. 2021, 22, 45–52.

Shah, S.J.; Kitzman, D.W.; Borlaug, B.A.; van Heerebeek, L.; Zile, M.R.; Kass, D.A.; Paulus, W.J. Phenotype-Specific Treatment of Heart Failure with Preserved Ejection Fraction: A Multiorgan Roadmap. Circulation 2016, 134, 73–90.

Zawadzka, M.M.; Grabowski, M.; Kapłon- Cieślicka, A. Phenotyping in heart failure with preserved ejection fraction: A key to find effective treatment. Adv. Clin. Exp. Med. 2022, 31, 1163–1172.

Hwang, S.J.; Melenovsky, V.; Borlaug, B.A. Implications of coronary artery disease in heart failure with preserved ejection fraction. J. Am. Coll. Cardiol. 2014, 64, 1702–1713.

Tsujimoto, T.; Kajio, H. Spironolactone Use and Improved Outcomes in Patients with Heart Failure with Preserved Ejection Fraction with Resistant Hypertension. J. Am. Heart Assoc. 2020, 9, e018827.

Jackson, A.M.; Jhund, P.S.; Anand, I.S.; Düngen, H.-D.; Lam, C.S.P.; Lefkowitz, M.P.; Linssen, G.; Lund, L.H.; Maggioni, A.P.; Pfeffer, M.A.; et al. Sacubitril- valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. Eur. Heart J. 2021, 42, 3741–3752.

Hedman, Å.K.; Hage, C.; Sharma, A.; Brosnan, M.J.; Buckbinder, L.; Gan, L.M.; Shah, S.J.; Linde, C.M.; Donal, E.; Daubert, J.-C.; et al. Identification of novel pheno- groups in heart failure with preserved ejection fraction using machine learning. Heart 2020, 106, 342–349.

Verbrugge, F.H.; Omote, K.; Reddy, Y.N.V.; Sorimachi, H.; Obokata, M.; Borlaug, B.A. Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality. Eur. Heart J. 2022, 43, 1941–1951.

Packer, M. Leptin-Aldosterone-Neprilysin Axis: Identification of Its Distinctive Role in the Pathogenesis of the Three Phenotypes of Heart Failure in People with Obesity. Circulation 2018, 137, 1614–1631.

Aimo, A.; Senni, M.; Barison, A.; Panichella, G.; Passino, C.; Bayes-Genis, A.; Emdin, M. Management of heart failure with preserved ejection fraction: From neurohormonal antagonists to empagliflozin. Heart Fail. Rev. 2023, 28, 179–191.

Sotomi, Y.; Hikoso, S.; Nakatani, D.; Okada, K.; Dohi, T.; Sunaga, A.; Kida, H.; Sato, T.; Matsuoka, Y.; Kitamura, T.; et al. Medications for specific phenotypes of heart failure with preserved ejection fraction classified by a machine learning-based clustering model. Heart 2023. Online ahead of print.

Galli, E.; Bourg, C.; Kosmala, W.; Oger, E.; Donal,E. Phenomapping Heart Failure with Preserved Ejection Fraction Using Machine Learning Cluster Analysis: Prognostic and Therapeutic Implications. Heart Fail. Clin. 2021, 17, 499–518.

Packer, M.; Kitzman, D.W. Obesity-Related Heart Failure with a Preserved Ejection Fraction: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, and Sodium-Glucose Cotransporter-2. JACC Heart Fail. 2018, 6, 633–639.

Wiviott, S.D.; Raz, I.; Bonaca, M.P.; Mosenzon, O.; Kato, E.T.; Cahn, A.; Silverman, M.G.; Zelniker, T.A.; Kuder, J.F.; Murphy, S.A.; et al. DECLARE–TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N. Engl. J. Med. 2019, 380, 347–357.